License a precision neuromodulation platform
License a precision neuromodulation platform
Aleva's platform gives partners a shortcut. 100 granted patents across 10+ patent families, MEMS-based electrode architecture built on human clinical data, and a decade of neuromodulation know-how, available through structured licensing, tech transfer, or selective co-development.
Aleva's platform gives partners a shortcut. 100 granted patents across 10+ patent families, MEMS-based electrode architecture built on human clinical data, and a decade of neuromodulation know-how, available through structured licensing, tech transfer, or selective co-development.
Two core IP clusters
Two core IP clusters
Aleva's portfolio covers the hardware that interfaces with tissue and advanced form factors that extend it. Partners can license one cluster or combine both for broader coverage.
Aleva's portfolio covers the hardware that interfaces with tissue and advanced form factors that extend it. Partners can license one cluster or combine both for broader coverage.
Three high-value frontiers for neuromodulation partners
Three high-value frontiers for neuromodulation partners
Validated in Parkinson's disease and essential tremor. The same architecture extends into adjacent indications where precision and form factor create differentiated value.
Validated in Parkinson's disease and essential tremor. The same architecture extends into adjacent indications where precision and form factor create differentiated value.
From first conversation to technical onboarding
From first conversation to technical onboarding
How Aleva's platform transferred to an external program
How Aleva's platform transferred to an external program
What this proves
This collaboration is Aleva's working proof point that the platform can be packaged for external programs, scoped, transferred, and deployed by a partner with a different commercial footprint and indication focus.
The partner brought the commercial infrastructure and indication expertise. Aleva brought the technology license and architecture know-how. The arrangement covered both IP access and a structured development pathway, demonstrating that the platform is not a closed internal asset but a transferable foundation for partner-led programs.
The combination of technology license and distribution agreement also illustrates that partnership structures can go beyond pure IP licensing, aligning incentives across development and commercial stages.
Selected technical and commercial details available under NDA.
What this proves
This collaboration is Aleva's working proof point that the platform can be packaged for external programs, scoped, transferred, and deployed by a partner with a different commercial footprint and indication focus.
The partner brought the commercial infrastructure and indication expertise. Aleva brought the technology license and architecture know-how. The arrangement covered both IP access and a structured development pathway, demonstrating that the platform is not a closed internal asset but a transferable foundation for partner-led programs.
The combination of technology license and distribution agreement also illustrates that partnership structures can go beyond pure IP licensing, aligning incentives across development and commercial stages.
Selected technical and commercial details available under NDA.
What partners are actually acquiring
What partners are actually acquiring
